Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

Overview of attention for article published in Frontiers in oncology, February 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (72nd percentile)

So far, Dimensions has found 14 publications that cite this research output.

Article in Frontiers in Oncology (April 2024)

Article in Biomacromolecules (January 2024)

Article in Expert Review of Anticancer Therapy (August 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.